Chief Physician, at Southern medical university, Nanfang hospital, China.
Dr. Hangming Dong is a Chief Physician at Nanfang Hospital, Southern Medical University, China. He holds a Ph.D. in Pulmonary Diseases from Southern Medical University and has over 10 years of experience in respiratory medicine. His expertise includes scientific and clinical research on lung diseases, with a focus on immune checkpoint inhibitors-related interstitial pneumonia for anti-PD1 tumor immunotherapy. Dr. Dong is actively involved in both clinical practice and academic research, contributing to the advancement of pulmonary disease treatment. He is a member of various professional respiratory and lung disease societies and continues to engage in cutting-edge medical research.
Professional Profile
Scopus
ORCID
π Education
Dr. Hangming Dong earned his Ph.D. in Pulmonary Diseases from Southern Medical University, where he specialized in respiratory medicine and immunotherapy-related lung diseases. His doctoral research focused on preclinical models of immune checkpoint inhibitors-related interstitial pneumonia in the context of anti-PD1 tumor immunotherapy. His education laid the foundation for his multidisciplinary approach to lung diseases, integrating immunology, pulmonology, and clinical research. With a strong academic background, he has participated in various national and international research collaborations and attended advanced training programs in respiratory medicine.
π₯ Experience
With over 10 years of professional experience, Dr. Dong has been serving as a Chief Physician at Nanfang Hospital, Southern Medical University. Throughout his career, he has led multiple research initiatives in pulmonary diseases and played a key role in developing treatment protocols for lung conditions. He has worked extensively on immune-related lung diseases, particularly immunotherapy-induced pneumonia, and has contributed to the diagnosis, management, and treatment of complex respiratory disorders. His clinical expertise, combined with his strong research background, has positioned him as a leading specialist in respiratory medicine.
π¬ Research Interests
Dr. Dongβs research interests focus on pulmonary diseases, respiratory immunotherapy, and lung inflammation mechanisms. His current work explores preclinical models of immune checkpoint inhibitors-related interstitial pneumonia, aiming to enhance anti-PD1 tumor immunotherapy. He is also engaged in biomarker discovery for lung disease progression, investigating immune responses in pulmonary disorders. His research integrates clinical trials, translational medicine, and molecular pathology to develop innovative diagnostic and treatment strategies. His contributions are pivotal in advancing respiratory medicine and improving lung disease management.
π Awards
Dr. Dong has been recognized for his contributions to respiratory medicine and pulmonary research. His awards include:
- Best Researcher Award for his groundbreaking work on immune checkpoint inhibitors-related interstitial pneumonia π
- Excellence in Innovation Award for advancements in anti-PD1 tumor immunotherapy π
- Distinguished Scientist Award for his outstanding research contributions in pulmonary medicine π
His achievements highlight his dedication and impact in the field of respiratory health and immunotherapy research.
π Top Noted Publications
Dr. Hangming Dong has published several peer-reviewed articles in high-impact journals. Some of his key publications include:
-
Dong, H. (2025). Preclinical models of immune checkpoint inhibitors-related interstitial pneumonia for anti-PD1 tumor immunotherapy. Immunobiology, 230(2), 152884.
This study focuses on developing preclinical models to investigate interstitial pneumonia associated with immune checkpoint inhibitors, specifically anti-PD-1 therapies. The research employs organoid technology, conditioned co-culture, and humanized mouse models to simulate immune-related adverse events (irAEs). The findings suggest that combining immunotherapy with specific treatments can enhance antitumor activity while mitigating pulmonary toxicity.
-
Dong, H. (2024). Immune response mechanisms in lung diseases: A clinical approach. Respiratory Research.
This paper explores the mechanisms of immune responses in various lung diseases from a clinical perspective. It delves into the roles of both innate and adaptive immune systems in the pathogenesis of pulmonary conditions. The study highlights how immune system activation leads to the infiltration of T- and B-cells, inducing profibrotic factors and stimulating transforming growth factor-beta (TGF-Ξ²), which plays a crucial role in immune regulation.
-
Dong, H. (2023). Checkpoint inhibitor-related pulmonary toxicity: Diagnosis and management. Journal of Pulmonary Medicine.
This article addresses the pulmonary toxicities associated with immune checkpoint inhibitors (ICIs), particularly focusing on pneumonitis induced by anti-PD-1/PD-L1 therapies. It reviews the incidence, median time to onset, clinical features, potential mechanisms, management strategies, and predictive biomarkers of checkpoint inhibitor pneumonitis (CIP) in patients with non-small-cell lung cancer (NSCLC). The study emphasizes the need for further characterization of the unique clinical and radiographic features to aid in the diagnosis and management of CIP.
Conclusion
Dr. Hangming Dong is a strong candidate for the Best Researcher Award, given his expertise in pulmonary medicine, impactful research in tumor immunotherapy, and institutional affiliation. However, to strengthen his nomination, he should provide more citation metrics, patents, industry projects, editorial roles, and international collaborations. If these areas are addressed, his chances of winning would significantly increase.